← Browse by Condition
Medical Condition
follicular lymphoma fl
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — follicular lymphoma fl Clinical Trials
How many clinical trials are currently recruiting for follicular lymphoma fl?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for follicular lymphoma fl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for follicular lymphoma fl?
follicular lymphoma fl research spans Phase 1 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a follicular lymphoma fl clinical trial?
Eligibility criteria for follicular lymphoma fl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Top Sponsors
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT04830137 Phase 1
Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Enrollment
248 pts
Location
United States
Sponsor
Nurix Therapeutics, Inc.
NCT06703892 Phase 1
Recruiting
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Enrollment
18 pts
Location
Taiwan
Sponsor
GenomeFrontier Therapeutics TW...
NCT03460977 Phase 1
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Enrollment
453 pts
Location
United States, Bulga...
Sponsor
Pfizer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology